Corrigendum: Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
NIHR Journals Library
2018-02-01
|
| Series: | Health Technology Assessment |
| Online Access: | https://doi.org/10.3310/hta21020-c201802 |
| _version_ | 1818147284636925952 |
|---|---|
| author | Rhona Johnston Olalekan Uthman Ewen Cummins Christine Clar Pamela Royle Jill Colquitt Bee Kang Tan Andrew Clegg Saran Shantikumar Rachel Court J Paul O’Hare David McGrane Tim Holt Norman Waugh |
| author_facet | Rhona Johnston Olalekan Uthman Ewen Cummins Christine Clar Pamela Royle Jill Colquitt Bee Kang Tan Andrew Clegg Saran Shantikumar Rachel Court J Paul O’Hare David McGrane Tim Holt Norman Waugh |
| author_sort | Rhona Johnston |
| collection | DOAJ |
| first_indexed | 2024-12-11T12:32:48Z |
| format | Article |
| id | doaj.art-b154ad873e2544258b9edb28ab68922a |
| institution | Directory Open Access Journal |
| issn | 1366-5278 2046-4924 |
| language | English |
| last_indexed | 2024-12-11T12:32:48Z |
| publishDate | 2018-02-01 |
| publisher | NIHR Journals Library |
| record_format | Article |
| series | Health Technology Assessment |
| spelling | doaj.art-b154ad873e2544258b9edb28ab68922a2022-12-22T01:07:12ZengNIHR Journals LibraryHealth Technology Assessment1366-52782046-49242018-02-0121210.3310/hta21020-c20180213/177/01-c1Corrigendum: Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluationRhona Johnston0Olalekan Uthman1Ewen Cummins2Christine Clar3Pamela Royle4Jill Colquitt5Bee Kang Tan6Andrew Clegg7Saran Shantikumar8Rachel Court9J Paul O’Hare10David McGrane11Tim Holt12Norman Waugh13McMDC, Harrogate, UKWarwick Evidence, Division of Health Sciences, University of Warwick, Coventry, UKMcMDC, Harrogate, UKBerlin, GermanyWarwick Evidence, Division of Health Sciences, University of Warwick, Coventry, UKEffective Evidence, Waterlooville, UKWarwick Evidence, Division of Health Sciences, University of Warwick, Coventry, UKUniversity of Central Lancashire, Preston, UKWarwick Evidence, Division of Health Sciences, University of Warwick, Coventry, UKWarwick Evidence, Division of Health Sciences, University of Warwick, Coventry, UKWarwick Evidence, Division of Health Sciences, University of Warwick, Coventry, UKQueen Elizabeth University Hospital, Glasgow, UKUniversity of Oxford, Oxford, UKWarwick Evidence, Division of Health Sciences, University of Warwick, Coventry, UKhttps://doi.org/10.3310/hta21020-c201802 |
| spellingShingle | Rhona Johnston Olalekan Uthman Ewen Cummins Christine Clar Pamela Royle Jill Colquitt Bee Kang Tan Andrew Clegg Saran Shantikumar Rachel Court J Paul O’Hare David McGrane Tim Holt Norman Waugh Corrigendum: Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation Health Technology Assessment |
| title | Corrigendum: Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation |
| title_full | Corrigendum: Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation |
| title_fullStr | Corrigendum: Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation |
| title_full_unstemmed | Corrigendum: Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation |
| title_short | Corrigendum: Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation |
| title_sort | corrigendum canagliflozin dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes systematic review and economic evaluation |
| url | https://doi.org/10.3310/hta21020-c201802 |
| work_keys_str_mv | AT rhonajohnston corrigendumcanagliflozindapagliflozinandempagliflozinmonotherapyfortreatingtype2diabetessystematicreviewandeconomicevaluation AT olalekanuthman corrigendumcanagliflozindapagliflozinandempagliflozinmonotherapyfortreatingtype2diabetessystematicreviewandeconomicevaluation AT ewencummins corrigendumcanagliflozindapagliflozinandempagliflozinmonotherapyfortreatingtype2diabetessystematicreviewandeconomicevaluation AT christineclar corrigendumcanagliflozindapagliflozinandempagliflozinmonotherapyfortreatingtype2diabetessystematicreviewandeconomicevaluation AT pamelaroyle corrigendumcanagliflozindapagliflozinandempagliflozinmonotherapyfortreatingtype2diabetessystematicreviewandeconomicevaluation AT jillcolquitt corrigendumcanagliflozindapagliflozinandempagliflozinmonotherapyfortreatingtype2diabetessystematicreviewandeconomicevaluation AT beekangtan corrigendumcanagliflozindapagliflozinandempagliflozinmonotherapyfortreatingtype2diabetessystematicreviewandeconomicevaluation AT andrewclegg corrigendumcanagliflozindapagliflozinandempagliflozinmonotherapyfortreatingtype2diabetessystematicreviewandeconomicevaluation AT saranshantikumar corrigendumcanagliflozindapagliflozinandempagliflozinmonotherapyfortreatingtype2diabetessystematicreviewandeconomicevaluation AT rachelcourt corrigendumcanagliflozindapagliflozinandempagliflozinmonotherapyfortreatingtype2diabetessystematicreviewandeconomicevaluation AT jpaulohare corrigendumcanagliflozindapagliflozinandempagliflozinmonotherapyfortreatingtype2diabetessystematicreviewandeconomicevaluation AT davidmcgrane corrigendumcanagliflozindapagliflozinandempagliflozinmonotherapyfortreatingtype2diabetessystematicreviewandeconomicevaluation AT timholt corrigendumcanagliflozindapagliflozinandempagliflozinmonotherapyfortreatingtype2diabetessystematicreviewandeconomicevaluation AT normanwaugh corrigendumcanagliflozindapagliflozinandempagliflozinmonotherapyfortreatingtype2diabetessystematicreviewandeconomicevaluation |